Infantile Hemangiomas With Unusually Prolonged Growth Phase

Brandling‐Bennett, Heather A.; Metry, Denise; Baselga, Eulàlia; Lucky, Anne W.; Adams, Denise M.; Cordisco, Maria; Frieden, Ilona J.

doi:10.1001/archderm.144.12.1632

Cited by 86 publications

(79 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[4][5][6] In our cohort, treatment was first initiated at an average of 11.4 weeks, with only 20% of patients receiving treatment before 9 weeks. Thus, nearly all patients had initiation of treatment after the period of maximal growth was over.…”

Section: Figurementioning

confidence: 99%

Early Growth of Infantile Hemangiomas: What Parents’ Photographs Tell Us

2012

Self Cite

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVES: Infantile hemangiomas (IH) are recognized as growing rapidly during the first months of life, but details of early growth before 3 months of age have not been well-characterized. Our goal was to study early IH growth by using parental photographs of infant children with facial IHs to better understand early hemangioma growth, with the aim of improving guidance for physicians and parents of infants with high-risk IH. METHODS: Serial images of 30 infants showing IH at intervals of 1 to 2 weeks up to 6 months were analyzed for characteristics of color, thickness, and distortion of anatomic landmarks. The presence or absence of an IH precursor at birth was noted. Mean scores per age interval were compiled. Results were analyzed by using signed rank test. An assessment of “optimal time for referral” was made. RESULTS: IH growth was nonlinear; most rapid growth occurred between 5.5 and 7.5 weeks of age. The mean “optimal age for referral” was 4 weeks of age. Hemangioma precursors were present at birth in 65% of patients. CONCLUSIONS: The most rapid hemangioma growth occurs before 8 weeks of age, much earlier than previously appreciated. Specialty evaluation and initiation of treatment, however, typically occur after the age of most rapid growth. Our findings suggest a need for a paradigm shift in the timing of referral and initiation of treatment of high-risk IH so that therapy can be initiated before or early in the course of most rapid growth, rather than after it is already completed.

show abstract

Section: Figurementioning

confidence: 99%

Early Growth of Infantile Hemangiomas: What Parents’ Photographs Tell Us

2012

Self Cite

View full text Add to dashboard Cite

show abstract

“…Their finding of increased rebound in deep or mixed IH and segmental IH is consistent with other reports, [6][7][8] as is the increased risk of rebound observed in girls 2,[6][7][8] The aforementioned hemangioma subtypes may represent a unique subpopulation of IH programmed to proliferate longer. 11,12 In a series of IH with prolonged growth by Brandling-Bennett et al, 11 all 23 lesions were on the head and neck, another feature found in the current study; in that series, nearly 40% of IH involved the parotid gland, a detail not included in the current report. The data from Shah et al 10 expand the published observations on rebound as a function of duration of OP therapy and age at the time of discontinuation or taper.…”

mentioning

confidence: 39%

Hemangiomas and β-Blockers: On the Rebound

Mancini

2016

Pediatrics

View full text Add to dashboard Cite

“…It was mainly the deep component that recurred [41]. The patients in this study also mainly had deep segmental IH, which have been known to have a prolonged proliferative phase [42]. It is important to follow-up with patients after discontinuing propranolol (for up to 6 months) to assess for potential rebound and intervene as necessary, especially if the children are younger than 1 year of age.…”

Section: Safety/adverse Effectsmentioning

confidence: 97%

Propranolol for Infantile Hemangiomas: A Review

Hogeling

2012

Curr Derm Rep

View full text Add to dashboard Cite

Infantile hemangiomas (IHs) are the most common vascular tumors of infancy. Since it was discovered several years ago, propranolol hydrochloride has become a very popular and successful treatment for complicated and aesthetically disfiguring IHs. The recent literature on propranolol is reviewed, including a summary of larger studies, discussion of adverse effects, and the use of propranolol in complicated IHs, such as ulcerated IHs, airway, and hepatic IHs.

show abstract

Infantile Hemangiomas With Unusually Prolonged Growth Phase

Cited by 86 publications

References 24 publications

Early Growth of Infantile Hemangiomas: What Parents’ Photographs Tell Us

Early Growth of Infantile Hemangiomas: What Parents’ Photographs Tell Us

Hemangiomas and β-Blockers: On the Rebound

Propranolol for Infantile Hemangiomas: A Review

Contact Info

Product

Resources

About